Report of Foreign Issuer (6-k)
26 July 2018 - 2:51AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
25 July
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sir Philip Hampton
|
|
b)
|
Position/status
|
Non-Executive Chairman
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.57
|
2,809.891
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr Vindi Banga
|
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.57
|
461.625
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Vivienne Cox
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.57
|
341.201
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms Lynn Elsenhans
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.34
|
1,203.681
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Laurie Glimcher
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.34
|
1,329.780
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Jesse Goodman
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.34
|
470.009
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms Judy Lewent
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.34
|
515.863
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr Urs Rohner
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 April 2018 to 30 June 2018.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.57
|
461.625
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-07-25
|
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
25, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
